Skip to main content
SpringerLink
Log in

Tocilizumab monotherapy cost effective for RA in Italy

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. tumour necrosis factor-α

Reference

  • Batticciotto A, et al. Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate. Advances in Therapy : 4 Jul 2016. Available from: URL: http://doi.org/10.1007/s12325-016-0372-z

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tocilizumab monotherapy cost effective for RA in Italy. PharmacoEcon Outcomes News 757, 31 (2016). https://doi.org/10.1007/s40274-016-3220-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3220-0

Search

Navigation